Sexual enhancement supplement recalled over three undeclared drugs

primidone will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Flibanserin's journey from failed antidepressant to HSDD treatment is unique.
• Its development cost hundreds of millions of dollars over two decades.
• The FDA initially rejected it in 2010 and 2013 due to safety/efficacy concerns.
• Final 2015 approval came with the stringent REMS and boxed warning.
• The approval process involved patient testimony and advocacy efforts.
• It is classified as a multifunctional serotonin agonist and antagonist (MSAA).
• Does not bind significantly to dopamine, norepinephrine, or histamine receptors.
• Binding affinity is highest for serotonin 5-HT1A and 5-HT2A receptors.
• Its metabolite, 6-hydroxy-flibanserin, is inactive.

progesterone micronizedprogesterone micronized will increase the level or

Warnings & Precautions

pentamidine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pentobarbitalpentobarbital will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Strong CYP3A4 inducers substantially decrease flibanserin systemic exposure.pentobarbital and flibanserin both increase sedation. pentobarbital will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenobarbitalphenobarbital will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Consumer Information Use and Disclaimer

phenobarbital will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenytoinphenytoin will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenytoin will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pilocarpinepilocarpine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pilocarpine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. progesterone micronized will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

propofolpropofol will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

INDICATION AND IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING

micafunginmicafungin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. micafungin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Risk for sedation increased if flibanserin is coadministration with other CNS depressants.midazolam will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect. mifepristonemifepristone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Last Reviewed Date

mifepristone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mirtazapinemirtazapine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mirtazapine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mitapivatmitapivat decreases levels of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. Monitor patients for loss of therapeutic effect if taking sensitive CYP2C19 substrates. propofol will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• The prescribing guidelines emphasize cautious use in women on other psychotropic drugs.
• Flibanserin's approval was driven by a need for female-specific sexual health medications.
• Its mechanism involves serotonergic pathways impacting sexual response.
• The drug is typically part of a broader therapy including counseling or therapy.
• Studies indicate a small but statistically significant benefit for some women.
• It is important to rule out other medical or psychological causes before use.
• Flibanserin is contraindicated with certain medications, such as CYP3A4 inhibitors.
• Side effect management includes monitoring blood pressure and mental status.
• The medication's role is to improve quality of life by addressing sexual desire challenges.

quinineflibanserin increases levels of quinine by P-glycoprotein (MDR1) efflux transporter.

Increase monitoring of concentrations of drugs transported by P-gp that have a narrow therapeutic index if

Information & Authors

mitapivat decreases levels of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. mitotanemitotane will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mitotane will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mitoxantronemitoxantrone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mitoxantrone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

FDA-approved indications

modafinilmodafinil will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. modafinil will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. nafcillinnafcillin will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nafcillin will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. naldemedineflibanserin increases levels of naldemedine by P-glycoprotein (MDR1) efflux transporter. coadministered with flibanserin.quinine will increase the level or

The #1 Prescribed Treatment for frustrating Low Libido1

nizatidinenizatidine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nizatidine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. olanzapineolanzapine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.flibanserin, olanzapine. olanzapine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Vyleesi (bremelanotide)

omeprazoleomeprazole will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. Coadministration of flibanserin with strong CYP2C19 inhibitors may increase flibanserin exposure and increase the risk of hypotension, syncope, and CNS depression.omeprazole will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. omeprazole will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. orphenadrineorphenadrine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. orphenadrine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Flibanserin should be discontinued if no benefit is observed after several weeks.
• The medication's influence on mental health conditions is still being studied.
• Flibanserin was recognized as a breakthrough therapy for female sexual desire issues.
• Its use is guided by strict medical protocols due to safety concerns.
• Women are encouraged to report any adverse effects during treatment.
• Continued research aims to improve treatment options for female sexual health.
• Flibanserin is one of a few FDA-approved drugs for Female Sexual Desire Disorder.
• Clinical improvements may include increased frequency of satisfying sexual events.
• The drug's use should be combined with counseling when appropriate.

flibanserin increases levels of quinine by P-glycoprotein (MDR1) efflux transporter.

Dosing & Uses

Monitor naldemedine for potential adverse effects if coadministered with P-gp inhibitors. flibanserin increases levels of naldemedine by P-glycoprotein (MDR1) efflux transporter. nevirapinenevirapine will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nevirapine will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nifedipinenifedipine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Hazard Classifications

nifedipine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nisoldipinenisoldipine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nisoldipine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nitrous oxidenitrous oxide and flibanserin both increase sedation. nitrous oxide and flibanserin both increase sedation. rabeprazolerabeprazole will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Before Using

pimozidepimozide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.flibanserin, pimozide. pimozide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pravastatinpravastatin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pravastatin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Activity profile

prednisoloneprednisolone will increase the level or effect of flibanserin by aldehyde dehydrogenase inhibition. prednisolone will increase the level or effect of flibanserin by aldehyde dehydrogenase inhibition. primaquineprimaquine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. primaquine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. primidoneprimidone will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rabeprazole will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Addyi (flibanserin) contraindications

oxybutyninoxybutynin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. oxybutynin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. oxybutynin transdermal will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. palbociclibpalbociclib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. palbociclib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Brand Names

paroxetineparoxetine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. paroxetine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pazopanibpazopanib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pazopanib will vardenafil oral increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pentamidinepentamidine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ranolazineranolazine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Flibanserin acts as an agonist on dopamine receptors and antagonist on certain serotonin receptors.
• The medication can take several weeks to show benefits.
• It is not approved for use in postmenopausal women.
• Flibanserin was initially developed as an antidepressant.
• It has a pharmacokinetic profile with a half-life of around 13 hours.
• Dose adjustments are necessary for patients with liver impairment.
• The drug can cause hypotension, especially with alcohol or CYP3A4 inhibitors.
• Patients are monitored for side effects such as sleepiness and low blood pressure.
• Flibanserin's efficacy is moderate and varies among women.